|
|
Longwood Fund is a healthcare venture capital firm that founds, manages, and builds biotechnology companies. Longwood's mission is to identify technologies and to found companies that will advance new therapeutics that can not only make a difference in the lives of patients worldwide, but also create significant value for investors. Longwood's portfolio includes Alnara Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2010 for $180 million cash upfront and a $200 million earn-out, and Verastem, Inc., a biotechnology company focused on discovering and developing novel drugs that selectively target cancer stem cells. Members of the Longwood team have founded and built several successful biotechnology companies including Momenta Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Sirtris Pharmaceuticals, Inc., and Alnara Pharmaceuticals, Inc. The firm's first fund, Longwood Founders Fund, L.P., was capped at $85 million when it closed December of 2010. Members of the Longwood team have co-founded and run biotechs worth a combined ~$60 billion, holding roles of CEO, Chairperson, and Lead VC. The Longwood partners have founded over 20 biotech companies, which have launched ~20 drugs, and created sustained market caps of over $100 billion.
|
